 |
|
|
|
|
|
|
|
|
|
|
|
1 to 8 of 8 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Smith A. on PAPER: Sperling RA. et al., 2011, The thoughtful commentary by Sperling, Jack, and Aisen focused on their third hypothesis, i.e.,... 20 Dec 2011.
|
|
|
 |
|
|
Smith A. on PAPER: Selkoe DJ. et al., 2011, Selkoe’s article is timely and provocative. I am sure that many will agree with his view, “Of... 27 Sep 2011.
|
|
|
|
|
|
Smith A. on NEWS: Toronto: 6th Sense—GWAS Picks Up New AD Risk Variant, The enzyme MTHFD1L does not directly catalyze the conversion of homocysteine to methionine.... 20 Apr 2010.
|
|
|
|
|
|
Smith A. on NEWS: Research Brief—Flurizan Fails Final Hurdle, Company Discontinues Drug, The news about Flurizan is disappointing, especially after the promising Phase 2 report earlier... 9 Jul 2008.
|
|
|
|
|
|
Smith A. on PAPER: Tarroun A. et al., 2007, It is surprising to read a paper with this title in 2006. It was shown in 1992 that the answer... 28 Nov 2006.
|
|
|
|
|
|
Smith A. on PAPER: Snowdon DA. et al., 2000, Recommendation Only. 12 Dec 2005.
|
|
|
|
|
|
Smith A. on PAPER: den Heijer T. et al., 2003, The paper by Den Heijer et al. referred to in the above article reported that, in a normal... 3 Mar 2003.
|
|
|
|
|
|
Smith A. on LIVE DISCUSSION: Vascular Disease, Parkinson's, and Now Alzheimer's—Is Homocysteine the New All-Around Bad Guy?, I cannot accept the statement in the introduction that the association between elevated... 12 May 2002.
|
|
|
|
|
|
|
1 to 8 of 8 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
Check out our upcoming Webinar: 
